Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn’s disease

References

• Reshamwala, P.A., Kleiner, D.E., Heller, T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006, 44, 7–14.
   PubMed Web of Science ®Google Scholar
• Nakanuma, Y. Nodular regenerative hyperplasia of the liver: retrospective survey in autopsy series. J. Clin. Gastroenterol. 1990, 12, 460–465.
   PubMedGoogle Scholar
• Colina, F., Alberti, N., Solis, J.A., Martinez-Tello, F.J. Diffuse nodular regenerative hyperplasia of the liver (DNRH). A clinicopathologic study of 24 cases. Liver 1989, 9, 253–265.
   PubMedGoogle Scholar
• Blogowski, W. Facial transplantation as an option in reconstructive surgery: no mountains too high? ANZ. J. Surg. 2009, 79, 892–897.
   PubMedGoogle Scholar
• Elariny, H.A., Mizrahi, S.S., Hayes, D.H., Boudreaux, J.P., Hussey, J.L., Farr, G.H. Jr. Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation. Transpl. Int. 1994, 7, 309–313.
   PubMedGoogle Scholar
• Wanless, I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11, 787–797.
   PubMed Web of Science ®Google Scholar
• Vernier-Massouille, G., Cosnes, J., Lemann, M., Marteau, P., Reinisch, W., Laharie, D., Cadiot, G., Bouhnik, Y., De Vos, M., Boureille, A., Duclos, B., Seksik, P., Mary, J.Y., Colombel, J.F. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007, 56, 1404–1409.
   PubMed Web of Science ®Google Scholar
• Poppe, D., Tiede, I., Fritz, G., Becker, C., Bartsch, B., Wirtz, S., Strand, D., Tanaka, S., Galle, P.R., Bustelo, X.R., Neurath, M.F. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 2006, 176, 640–651.
   PubMed Web of Science ®Google Scholar
• de Boer, N.K., Tuynman, H., Bloemena, E., Westerga, J., Van Der Peet, D.L., Mulder, C.J., Cuesta, M.A., Meuwissen, S.G., Van Nieuwkerk, C.M., Van Bodegraven, A.A. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand. J. Gastroenterol. 2008, 43, 604–608.
   PubMed Web of Science ®Google Scholar
• Dubinsky, M.C., Vasiliauskas, E.A., Singh, H., Abreu, M.T., Papadakis, K.A., Tran, T., Martin, P., Vierling, J.M., Geller, S.A., Targan, S.R., Poordad, F.F. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125, 298–303.
   PubMed Web of Science ®Google Scholar
• Seksik, P., Mary, J.Y., Beaugerie, L., Colombel, J.F., Vernier, G., Cosnes, J. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm. Bowel. Dis. 2010 (In Press).
   Google Scholar
• Hillaire, S., Bonte, E., Denninger, M.H., Casadevall, N., Cadranel, J.F., Lebrec, D., Valla, D., Degott, C. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002, 51, 275–280.
   PubMed Web of Science ®Google Scholar
• Perez, R.F., Zea, M.A.C., Orte, M.F.J. Anti-phospholipid antibodies may play a role in pathogenesis of nodular regenerative hyperplasia of the liver. Br. J. Rheumatol. 1990, 29(Suppl 2), 107.
   Google Scholar
• Austin, A., Campbell, E., Lane, P., Elias, E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anti-cardiolipin antibody. Gut 2004, 53, 1032–1034.
   PubMedGoogle Scholar
• Haboubi, N.Y., Ali, H.H., Whitwell, H.L., Ackrill, P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am. J. Gastroenterol. 1988, 83, 256–261.
   PubMed Web of Science ®Google Scholar
• Hubert, C., Sempoux, C., Horsmans, Y., Rahier, J., Humblet, Y., Machiels, J.P., Ceratti, A., Canon, J.L., Gigot, J.F. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver. Int. 2007, 27, 938–943.
   PubMedGoogle Scholar
• Ziol, M., Poirel, H., Kountchou, G.N., Boyer, O., Mohand, D., Mouthon, L., Tepper, M., Guillet, J.G., Guettier, C., Raphael, M., Beaugrand, M. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum. Pathol. 2004, 35, 1241–1251.
   PubMed Web of Science ®Google Scholar
• deLeve, L.D., Wang, X., Kuhlenkamp, J.F., Kaplowitz, N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996, 23, 589–599.
   PubMed Web of Science ®Google Scholar
• de Boer, N.K., van Bodegraven, A.A., Jharap, B., de Graaf, P., Mulder, C.J. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 686–694.
   PubMedGoogle Scholar
• de Boer, N.K., Mulder, C.J., van Bodegraven, A.A. Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity. Liver. Transpl. 2005, 11, 1300–1301.
   PubMedGoogle Scholar
• Breen, D.P., Marinaki, A.M., Arenas, M., Hayes, P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver. Transpl. 2005, 11, 826–833.
   PubMed Web of Science ®Google Scholar
• Al Hadithy, A.F., de Boer, N.K., Derijks, L.J., Escher, J.C., Mulder, C.J., Brouwers, J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig. Liver. Dis. 2005, 37, 282–297.
   PubMedGoogle Scholar
• Winter, J., Walker, A., Shapiro, D., Gaffney, D., Spooner, R.J., Mills, P.R. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2004, 20, 593–599.
   PubMed Web of Science ®Google Scholar
• Dachman, A.H., Ros, P.R., Goodman, Z.D., Olmsted, W.W., Ishak, K.G. Nodular regenerative hyperplasia of the liver: clinical and radiologic observations. AJR. Am. J. Roentgenol. 1987, 148, 717–722.
   PubMedGoogle Scholar
• Wang, H.M., Lo, G.H., Hsu, P.I., Lin, C.K., Chan, H.H., Chen, W.C., Lai, K.H., Wang, B.W., Lin, S.L. Nodular regenerative hyperplasia of the liver. J. Chin. Med. Assoc. 2008, 71, 523–527.
   PubMedGoogle Scholar
• Wanless, I.R., Peterson, P., Das, A., Boitnott, J.K., Moore, G.W., Bernier, V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990, 12, 1166–1174.
   PubMed Web of Science ®Google Scholar
• O’Brien, K., Hussain, N., Warady, B.A., Kleiner, D.E., Kleta, R., Bernardini, I., Heller, T., Gahl, W.A. Nodular regenerative hyperplasia and severe portal hypertension in cystinosis. Clin. Gastroenterol. Hepatol. 2006, 4, 387–394.
   PubMed Web of Science ®Google Scholar
• Nakanuma, Y., Hoso, M., Sasaki, M., Terada, T., Katayanagi, K., Nonomura, A., Kurumaya, H., Harada, A., Obata, H. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996, 28, 195–204.
   PubMed Web of Science ®Google Scholar
• Seiderer, J., Zech, C.J., Diebold, J., Schoenberg, S.O., Brand, S., Tillack, C., Göke, B., Ochsenkühn, T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol. 2006, 18, 553–555.
   PubMed Web of Science ®Google Scholar
• de Boer, N.K., Zondervan, P.E., Gilissen, L.P., den Hartog, G., Westerveld, B.D., Derijks, L.J., Bloemena, E., Engels, L.G., van Bodegraven, A.A., Mulder, C.J. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver. Dis. 2008, 40, 108–113.
   PubMedGoogle Scholar
• de Boer, N.K., Reinisch, W., Teml, A., van Bodegraven, A.A., Schwab, M., Lukas, M., Ochsenkühn, T., Petritsch, W., Knoflach, P., Almer, S., van der Merwe, S.W., Herrlinger, K.R., Seiderer, J., Vogelsang, H., Mulder, C.J. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006, 73, 25–31.
   PubMed Web of Science ®Google Scholar
• Van Asseldonk, D.P., de Boer, N.K., Peters, G.J., Veldkamp, A.I., Mulder, C.J., Van Bodegraven, A.A. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr. Drug. Metab. 2009, 10, 981–997.
   PubMed Web of Science ®Google Scholar